Final Thoughts As GLP-1 medications like Semaglutide and Mounjaro gain traction for weight management and diabetes control, effectively managing their side effects becomes increasingly important
The inclusion of oral GLP-1s at $149/month could make these medications even more accessible for patients who prefer a pill over injections
This includes 6% of adults who say they are currently taking one of these drugs, which include Ozempic, Wegovy and MounjaroThe shares of adults who report ever taking these drugs is highest among people with diabetes (43%), followed by those with heart disease (26%) and those who have obesity or overweight (22%), the poll finds
In the Phase 2 trial, retatrutide was given as a once-weekly subcutaneous injection, starting at a low dose and escalating gradually up to 12 mg weekly
Important context: This population sizing is an extrapolation based on survey incidence and public population estimates
GLP-1, or glucagon-like peptide-1, is a powerful hormone that plays a crucial role in regulating blood sugar, enhancing insulin secretion, and promoting feelings of fullness
